주메뉴 바로가기 본문 바로가기
  • KDCA
  • Contact us
  • E-Submission

PHRP : Osong Public Health and Research Perspectives

OPEN ACCESS. pISSN: 2210-9099. eISSN: 2233-6052
Search
Advanced Search
About
Browse articles
Editorial policies
For authors

Articles

Page Path

Original Article

Epidemiological Characterization of Imported Systemic Mycoses Occurred in Korea

Seung-Hak Choa, Young-Bin Yub, Je-Seop Parkc, Keun-Dol Yookd, Young-Kwon Kimb,*
Osong Public Health and Research Perspectives 2018;9(5):255-260.
Published online: September 30, 2018

aDivision of Bacterial Disease Research, Center for Infectious Disease Research, Korea National Institute of Health, Cheongju, Korea

bDepartment of Biomedical Laboratory Science, College of Medical Sciences, Konyang University, Daejeon, Korea

cFire Science Laboratory, National Fire Service Academy, Asan, Korea

dDepartment of Clinical Laboratory Science, Daejeon Health College, Daejeon, Korea

*Corresponding author: Young-Kwon Kim, Department of Biomedical Laboratory Science, College of Medical Sciences, Konyang University, Daejeon, Korea, E-mail: ykkim3245@konyang.ac.kr
† Seung-Hak Cho and Young-Bin Yu contributed equally to the work.
‡ Young-Kwon Kim and Keun-Dol Yook contributed equally to the work.
• Received: August 18, 2018   • Revised: September 8, 2018   • Accepted: September 13, 2018

Copyright ©2018, Korea Centers for Disease Control and Prevention

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

  • 12,696 Views
  • 145 Download
  • 4 Crossref
  • 4 Scopus
prev next

Full Article

Download PDF Download PDF
  • Objectives
    Imported systemic mycoses is a severe fungal infection that can cause diseases in healthy people. However, there is a serious lack of epidemiological data about imported systemic mycoses. Therefore, an epidemiological characterization of imported systemic mycoses in Korea was performed.
  • Methods
    We collected health insurance data between 2008 and 2012 from the Health Insurance Corporation and analyzed the data to determine the prevalence and treatment management of imported systemic mycoses.
  • Results
    The prevalence of imported systemic mycoses between 2008 and 2012 increased slowly by 0.49/100,000 to 0.53/100,000 persons. The prevalence of coccidioidomycosis increased from 0.28/100,000 in 2008 to 0.36/100,000 persons in 2012. A mean of 229.6 cases occurred each year. Children and the elderly showed higher prevalence than adults in the 20- to 59-year-old age group. The rate of infection according to region ranged from 0.18/100,000 persons in Ulsan, to 0.59/100,000 persons in Gyeonggi. The prevalence in females was higher than that in males. Inpatient treatment was 3.3% (38 cases), with 96.7% treated as outpatients. Hospitalizations cost 272.7 million won and outpatient treatments cost 111.7 million won. The treatment cost for coccidioidomycosis from 2008 to 2012 was 330.9 million won, with personal charges of 79.2 million won and insurance charges of 251.7 million won. Most of the expenses for the coccidioidomycosis treatment were for inpatient treatment.
  • Conclusion
    The results in this study may be a useful resource for determining the changes in the trend of imported systemic mycoses.
  • Keywords: blastomycosis; coccidioidomycosis; epidemiology; histoplasmosis; mycoses
Imported systemic mycoses generally occurs amongst people that stay in an area where there is a high frequency of travel or business trips, and particularly in people who reside long-term in these areas such as archaeologists, speleologists, and immigrants [1–3]. Coccidioidomycosis, blastomycosis, histoplasmosis and paracoccidioidomycosis belong to imported systemic mycoses. Coccidioidomycosis is a fungal infectious disease that occurs due to inhalation of arthroconidia of Coccidioides species where it mostly forms primary lesions in the lungs and disseminates to other areas. Most patients recover from these infections without treatment, but about 5% of patients with low immunity suffer a systemic infection in areas such as skin, bone, joint, and meninges with fatal results [4–6]. Blastomycosis occurs due to Blastomyces dermatitidis and has very diverse clinical symptoms. After primary lung infection it progresses into a systemic infection on the skin, in the urinary reproductive system, and the central nervous system [7]. Histoplasmosis occurs due to inflow of Histoplasma capsulatum and H duboisii spores into the respiratory system where it invades the alveoli [8]. Paracoccidioidomycosis is an imported systemic mycosis that occurs due to Paracoccidioides brasilliensis which disseminates into the lungs, lymph nodes, over the skin, and airways, and progression is acute [1].
Although imported systemic mycoses is a severe infectious disease with a high risk of death, there is a serious lack of overall epidemiological and clinical research about this disease. This disease is not registered as a national notifiable infectious disease which means there is no obligation to report the infection. It is estimated that there will be a continual increase in overseas travelers and an influx of immigrants that would increase the risk of dissemination of imported systemic mycoses. Therefore, this study was conducted to investigate the domestic occurrence of imported systemic mycoses and analyze the epidemiological characteristics to provide basic data for reference as a national notifiable infectious disease in the future.
1. Study design
Health insurance data between 2008 and 2012 were collected from the Health Insurance Corporation and analyzed for cases of coccidioidomycosis (KoICD, Korea International Classification of Diseases: B38), histoplasmosis (B39), blastomycosis (B40), and paracoccidioidomycosis (B41). The number of incidences were analyzed by considering medical records for 1 case if the case was duplicated within 2 months.
2. Epidemiological analysis
In order to determine the significance of imported systemic mycoses causing diseases, an epidemiological analysis of annual and regional prevalence and age- and gender-specific patterns of the prevalence for each imported systemic mycoses was performed. The annual prevalence of imported systemic mycoses was calculated, where patients with the disease who had been treated multiple times were counted as 1 case per year in the data analysis. The regional prevalence was calculated according to the locations of the medical institutions where the treatments had been provided.
3. Duration of hospitalization and cost analysis of therapy
The number of convalescence days of inpatients and outpatients for imported systemic mycoses were calculated for the last 5 years. Medical care costs were calculated and classified as personal charges and insurance charges from the insurance items in the Health Insurance Corporation database. No insurance charge item was excluded from the medical care cost.
The frequency of imported systemic mycoses is continuously increasing which is threatening national health. This is thought to be due to an increase in overseas travelers visiting Korea and the population participating in more outdoor activities. Several cases of imported systemic mycoses have been reported in Korea [9–11]. This current study demonstrates fundamental epidemiological characteristics of imported systemic mycoses and medical treatments for these patients between the years of 2008 and 2012 in Korea.
1. Epidemiological characterization of imported systemic mycoses between 2008 and 2012 in Korea
A total of 1,148 infections with imported systemic mycoses were analyzed between 2008 and 2012. Approximately 229.6 cases occurred each year. Among the imported systemic mycoses, the prevalence of coccidioidomycosis (660 cases) was highest followed by histoplasmosis (245 cases), blastomycosis (171 cases), and lastly paracoccidioidomycosis (72 cases). Annual prevalence of imported systemic mycoses increased slowly from 0.49/100,000 persons in 2008, to 0.53/100,000 persons in 2012. The annual prevalence of coccidioidomycosis increased from 0.28/100,000 persons in 2008, to 0.36/100,000 persons in 2012, whereas the prevalence of other imported systemic mycoses was similar in each year or decreased (Table 1). The prevalence of coccidioidomycosis in females was higher than in males (Table 2). It was reported that female hormones and differences in genetic factors could affect coccidioidomycosis [12,13]. These studies also showed that progesterone and testosterone highly stimulated Coccidioides strains that cause infection. As shown in Table 3, age-specific patterns were observed in the imported systemic mycoses. By age group, there was a high rate of prevalence in people aged 0 to 9 years (0.71/100,000 persons) and in people aged 60 to 89 years (0.73/100,000 persons), whereas the prevalence rate was low in people aged 20 to 59 years. The prevalence rate of coccidioidomycosis was high in people aged 0 to 9 years and the prevalence of blastomycosis was high in people aged 60 to 89 years (Table 3). The regional prevalence is shown in Table 4. Gyeonggi (348 cases) and Seoul (219 cases) had the highest rates of infection, and Ulsan (10 cases) had the lowest rate of occurrence. The rate of infection according to region ranged from 0.18/100,000 persons in Ulsan to 0.59/100,000 persons in Gyeonggi. The reasons for the rate difference between the regions was not well understood. Further detailed epidemiological and clinical data are necessary to understand imported systemic mycoses infection and immunity in the future.
The regional prevalence of coccidioidomycosis was similar across the country, with the range in incidences from 0.05/100,000 persons in Ulsan, to 0.44/100,000 persons in Gyeonggi (Table 4). In the United States of America, about 150,000 patients have coccidioidomycosis every year [14]. Baddley et al [2] reported that the occurrence ratio of systemic mycosis within the USA was 46.1% for histoplasmosis, 44.5% for coccidioidomycosis, and 9.5% for blastomycosis. The average age of the patients were 75.7 years and 55% of these patients were male. Kirkland and Fierer [15] showed that the prevalence rate of coccidioidomycosis was highest in spring and late summer in Arizona, and in late summer and early fall in California. The highest rate of occurrence was reported in people that reside in semi-desert areas and in people who are involved in frequent outdoor leisure activities. Considering the 1–3 weeks incubation period of coccidioidomycosis, it was determined that the period of visiting a medical institution due to symptoms were similar. Furthermore, most of the investigation subjects had a history of temporarily residing or visiting the area during the spring and summer. However, a non-imported case of coccidioidomycosis was also reported [16]. In Japan, the prevalence rate of coccidioidomycosis has been rapidly increasing since the 1980s until recently. Fujio et al [17] reported that until 1998, 16 cases of coccidioidomycosis, 22 cases of histoplasmosis, 13 cases of paracoccidioidomycosis, and 1 case of Penicilliosis marneffei were reported. However, 31 cases of coccidioidomycosis, 34 cases of histoplasmosis, 17 cases of paracoccidioidomycosis, and 1 case of P marneffei were reported in 2005 [18]. Recently, the prevalence of imported systemic mycoses has increased in Japan [19].
2. Convalescence days and medical care charges according to different imported systemic mycoses
As shown in Table 5, amongst the 1,148 patients infected with imported systemic mycoses, inpatient treatment was 3.3% (38 cases), and 96.7% were treated as outpatients. Inpatient treatment of each coccidioidomycosis was 2.9% (19/660 persons), 4.1% (10/245 persons) of histoplasmosis, 3.5% (6/171 persons) of blastomycosis, and 4.2% (3/72 persons) of paracoccidioidomycosis. Total medical expense cost was 384.4 million won, with personal charges of 93.4 million won and insurance charges of 291 million won. Among the total expenses, hospitalization cost 272.7 million won and outpatient treatments cost 111.7 million won. About 86% (330.9 million won/384.4 million won) of the total expenses were used for the treatment of coccidioidomycosis. The treatment cost for coccidioidomycosis from 2008 to 2012 was 330.9 million won, with personal charges of 79.2 million won and insurance charges of 251.7 million won. Most of the expenses for the coccidioidomycosis treatment was for inpatient treatment (Table 4).
Due to frequent travels abroad, imported systemic mycoses may increase in the future in Korea. Therefore, development of diagnosis and therapy against imported systemic mycoses, especially coccidioidomycosis, is necessary. Increase of eosinophil numbers in the blood can be seen in various disease groups, suggesting that this may be an important marker for disease in diverse cases in endemic disease areas. Therefore, increased eosinophil counts in peripheral blood tests and bronchial biopsy with a medical history of traveling to endemic disease areas can be leading evidence in suspecting imported systemic mycoses infection [20,21]. However, it is not possible to diagnose coccidioidomycosis just with elevated eosinophil counts because eosinophilia is a common outcome of allergies, infectious disease, and medication. For early diagnosis of imported systemic mycoses, the following observations are recommended; i) Nodular erythema, skin lesions such as erythema multiforme, ii) fever spanning over 2 weeks, fatigue, joint pain, iii) unexplainable peripheral blood eosinophilia, iv) presence of respiratory symptoms, 1 or more cases of hospital care, chest x-ray imaging, presence of specific symptoms or prognosis e.g. diagnosed with antibiotics, v) history of travel to endemic disease areas such as the USA, then imported systemic mycoses should be suspected.
Outbreaks of coccidioidomycosis in the future are highly possible therefore, diagnosis standards for imported systemic mycoses need to be established with a matter of urgency. The data in this study may be a useful resource for determining changes in the trends of imported systemic mycoses.
Acknowledgements
This work was supported by the Research Program funded by the Korea Centers for Disease Control and Prevention (fund code# 2013-E2400200).

Conflicts of Interest

No potential conflicts of interest relevant to this article was reported.

  • 1. Bonifaz A, Vázquez-González D, Perusquía-Ortiz AM. Endemic systemic mycoses: coccidioidomycosis, histoplasmosis, paracoccidioidomycosis and blastomycosis. J Dtsch Dermatol Ges 2011;9(9). 705−14.
  • 2. Baddley JW, Winthrop KL, Patkar NM, et al. Geographic distribution of endemic fungal infections among older persons, United States. Emerg Infect Dis 2011;17(9). 1664−9.
  • 3. Panackal AA, Hajjeh RA, Cetron MS, et al. Fungal infections among returning travelers. Clin Infect Dis 2002;35(9). 1088−95.
  • 4. Park DJ, Jang YH, Lee SJ, et al. A case of coccidioidomycosis showing cutaneous and pulmonary nodules. Kor J Med Mycol 2004;9(3). 190−5.
  • 5. Szeyko LA, Taljanovic MS, Dzioba RB, et al. Vertebral coccidioidomycosis: presentation and multidisciplinary management. Am J Med 2012;125(3). 304−14.
  • 6. Kirkland TN, Fierer J. Coccidioidomycosis: a reemerging infectious disease. Emerg Infect Dis 1996;2(3). 192−9.
  • 7. Cho JH, Suh JS, Kim JH. Systemic blastomycosis with osseous involvement of the foot: A case report. J Korean Foot Ankle Soc 2005;9(2). 216−9. [in Korean].
  • 8. Jeong HW, Sohn JW, Kim MJ, et al. Disseminated histoplasmosis and tuberculosis in a patient with HIV infection. Yonsei Med J 2007;48(3). 531−4.
  • 9. Chang SH, Shim SH, Kwak JE, et al. A case report of cutaneous coccidioidomycosis. Korean J Pathol 2008;42(4). 223−5. [in Korean].
  • 10. Jhun BW, Kim DM, Park JH, et al. A case of pulmonary blastomycosis mimicking pulmonary tuberculosis. Tuberc Respir Dis 2012;72(1). 77−81.
  • 11. Seo CG, Seo YW, Park HP, et al. A case of blastomycosis after traveling around non-imported area. Tuberc Respir Dis 2005;58(6). 619−23.
  • 12. Drutz DJ, Huppert M, Sun SH, et al. Human sex hormones stimulate the growth and maturation of Coccidioides immitis. Infect Immun 1981;32(2). 897−907.
  • 13. Louie L, Ng S, Hajjeh R, et al. Influence of host genetics on the severity of coccidioidomycosis. Emerg Infect Dis 1999;5(5). 672−80.
  • 14. Centers for Disease Control and Prevention (CDC). Increase in Coccidioidomycosis-California, 2000–2007. MMWR Morb Mortal Wkly Rep 2009;58(5). 105−9.
  • 15. Kirkland TN, Fierer J. Coccidioidomycosis: a reemerging infectious disease. Emerg Infect Dis 1996;2(3). 192−9.
  • 16. Desai SA, Minai OA, Gordon SM, et al. Coccidioidomycosis in non-imported areas: a case series. Respir Med 2001;95(4). 305−9.
  • 17. Fujio J, Nishimura K, Miyaji M. Epidemiological survey of the imported mycoses in Japan. Jpn J Med Mycol 1999;40(2). 103−9.
  • 18. Kamei K. Imported mycoses in Japan: their present status and problems. Jpn J Med Mycol 2005;46(1). 17−20.
  • 19. National Institute of Infectious Diseases. Mycoses in Japan as of 2012. Byogen Biseibutsu Kenshutsu Joho Geppo 2013;34(1). 1−2.
  • 20. Kawabata M, Homma S, Sakamoto S, et al. A case of pulmonary coccidioidomycosis presented with bilateral infiltrative opacities and eosinophilia. Kansenshogaku Zasshi 2004;78(6). 514−8.
  • 21. Koepke A, Albus C, Barth A, et al. Coccidioidomycosis: differential diagnosis of lung infiltrates with peripheral eosinophilia. Dtsch Med Wochenschr 1989;114(6). 218−21.
Table 1
Prevalence rates of imported systemic mycoses by year.
Table 1
Year Population No. of patients (per 100,000)
Systemic mycoses Coccidioidomycosis Histoplasmosis Blastomycosis Paracoccidioidomycosis
2008 49,540,367 243 (0.49) 138 (0.28) 52 (0.10) 32 (0.06) 21 (0.04)
2009 49,773,145 191 (0.38) 98 (0.20) 50 (0.10) 30 (0.06) 13 (0.03)
2010 50,515,666 212 (0.42) 115 (0.23) 54 (0.11) 30 (0.06) 13 (0.03)
2011 50,734,284 234 (0.46) 126 (0.25) 45 (0.09) 44 (0.06) 19 (0.04)
2012 50,948,272 268 (0.53) 183 (0.36) 44 (0.09) 35 (0.07) 6 (0.01)
Total 251,511,734 1,148 660 245 171 72

Data are presented as n (%).

Table 2
Prevalence rates of imported systemic mycoses by gender.
Table 2
Gender Population No. of patients (per 100,000)
Systemic mycoses Coccidioidomycosis Histoplasmosis Blastomycosis Paracoccidioidomycosis
Male 126,218,201 473 (0.38) 267 (0.21) 56 (0.04) 110 (0.09) 40 (0.03)
Female 125,293,533 675 (0.54) 393 (0.31) 189 (0.15) 60 (0.05) 32 (0.03)
Total 251,511,734 1,148 660 245 171 72

Data are presented as n (%).

Table 3
Prevalence rates of imported systemic mycoses by age.
Table 3
Age (y) Population No. of patients (per 100,000)
Systemic mycoses Coccidioidomycosis Histoplasmosis Blastomycosis Paracoccidioidomycosis
0–9 24,121,916 172 (0.71) 114 (0.47) 38 (0.16) 13 (0.05) 7 (0.03)
10–19 33,591,851 63 (0.19) 39 (0.12) 11 (0.03) 6 (0.02) 7 (0.02)
20–29 34,475,220 102 (0.30) 62 (0.18) 28 (0.08) 8 (0.02) 4 (0.01)
30–39 41,636,105 159 (0.36) 103 (0.25) 35 (0.08) 8 (0.02) 13 (0.03)
40–49 43,928,536 206 (0.47) 118 (0.27) 44 (0.10) 28 (0.06) 16 (0.04)
50–59 35,035,189 179 (0.51) 101 (0.29) 38 (0.11) 26 (0.07) 14 (0.04)
60–69 20,749,025 133 (0.64) 63 (0.30) 26 (0.13) 40 (0.19) 4 (0.02)
70–79 13,170,523 97 (0.74) 48 (0.36) 15 (0.11) 29 (0.22) 5 (0.04)
80–89 4,227,934 34 (0.80) 10 (0.24) 9 (0.21) 13 (0.31) 2 (0.05)
90- 575,435 3 (0.52) 2 (0.35) 1 (0.17) 0 (0.00) 0 (0.00)
Total 251,511,734 1,148 660 245 171 72

Data are presented as n (%).

Table 4
Prevalence rates of imported systemic mycoses by region.
Table 4
Region Population No. of patients (per 100,000)
Systemic mycoses Coccidioidomycosis Histoplasmosis Blastomycosis Paracoccidioidomycosis
Gyeonggi 58,577,280 348 (0.59) 260 (0.44) 52 (0.09) 29 (0.05) 7 (0.01)
Seoul 51,173,741 219 (0.43) 101 (0.20) 69 (0.13) 38 (0.07) 11 (0.02)
Busan 17,772,034 59 (0.33) 27 (0.15) 17 (0.10) 9 (0.05) 6 (0.03)
Gyeongnam 16,401,116 92 (0.56) 38 (0.23) 14 (0.09) 9 (0.05) 31 (0.19)
Incheon 13,813,896 53 (0.38) 22 (0.16) 20 (0.14) 7 (0.05) 4 (0.03)
Gyeongbuk 13,438,345 35 (0.26) 17 (0.13) 7 (0.05) 8 (0.06) 3 (0.02)
Daegu 12,514,166 73 (0.58) 41 (0.33) 9 (0.07) 21 (0.17) 2 (0.02)
Chungnam 10,268,764 42 (0.41) 24 (0.23) 15 (0.15) 1 (0.01) 2 (0.02)
Jeonnam 9,581,516 56 (0.58) 40 (0.42) 11 (0.11) 4 (0.04) 1 (0.01)
Jeonbuk 9,333,685 35 (0.38) 17 (0.18) 6 (0.06) 10 (0.11) 2 (0.02)
Chungbuk 7,732,194 37 (0.48) 20 (0.26) 8 (0.10) 8 (0.10) 1 (0.01)
Gangwon 7,633,411 22 (0.29) 14 (0.18) 4 (0.05) 4 (0.05) 0 (0.00)
Daejeon 7,515,995 21 (0.28) 9 (0.12) 2 (0.03) 9 (0.12) 1 (0.01)
Gwangju 7,250,728 33 (0.46) 23 (0.32) 5 (0.07) 4 (0.06) 1 (0.01)
Ulsan 5,643,391 10 (0.18) 3 (0.05) 5 (0.09) 2 (0.04) 0 (0.00)
Jeju 2,861,472 13 (0.46) 4 (0.14) 1 (0.04) 8 (0.28) 0 (0.00)
Total 251,511,734 1,148 660 245 171 72

Data are presented as n (%).

Table 5
Medical costs of imported systemic mycoses in Korea.
Table 5
No. of patients Self-cost (Korean won) Insurance cost (Korean won) Total cost (Korean won)
Systemic mycosis Inpatient 38 61,757,950 210,985,310 272,743,260
Outpatient 1,110 31,680,200 80,102,530 111,782,730
Coccidioidomycosis Inpatient 19 56,691,790 190,083,600 246,775,390
Outpatient 641 22,511,660 61,636,340 84,148,000
Histoplasmosis Inpatient 10 1,767,940 8,922,980 10,690,920
Outpatient 235 4,782,740 7,085,050 11,867,790
Blastomycosis Inpatient 6 3,072,960 9,336,910 12,409,870
Outpatient 165 2,354,140 5,113,340 7,467,480
Paracoccidioidomycosis Inpatient 3 225,260 2,641,820 2,867,080
Outpatient 69 2,031,660 6,267,800 8,299,460

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

Include:

Epidemiological Characterization of Imported Systemic Mycoses Occurred in Korea
Osong Public Health Res Perspect. 2018;9(5):255-260.   Published online October 31, 2018
DOI: https://doi.org/10.24171/j.phrp.2018.9.5.07
Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
Format:
Include:
Epidemiological Characterization of Imported Systemic Mycoses Occurred in Korea
Osong Public Health Res Perspect. 2018;9(5):255-260.   Published online October 31, 2018
DOI: https://doi.org/10.24171/j.phrp.2018.9.5.07
Close
Epidemiological Characterization of Imported Systemic Mycoses Occurred in Korea
Epidemiological Characterization of Imported Systemic Mycoses Occurred in Korea

Prevalence rates of imported systemic mycoses by year.

Year Population No. of patients (per 100,000)
Systemic mycoses Coccidioidomycosis Histoplasmosis Blastomycosis Paracoccidioidomycosis
2008 49,540,367 243 (0.49) 138 (0.28) 52 (0.10) 32 (0.06) 21 (0.04)
2009 49,773,145 191 (0.38) 98 (0.20) 50 (0.10) 30 (0.06) 13 (0.03)
2010 50,515,666 212 (0.42) 115 (0.23) 54 (0.11) 30 (0.06) 13 (0.03)
2011 50,734,284 234 (0.46) 126 (0.25) 45 (0.09) 44 (0.06) 19 (0.04)
2012 50,948,272 268 (0.53) 183 (0.36) 44 (0.09) 35 (0.07) 6 (0.01)
Total 251,511,734 1,148 660 245 171 72

Data are presented as n (%).

Prevalence rates of imported systemic mycoses by gender.

Gender Population No. of patients (per 100,000)
Systemic mycoses Coccidioidomycosis Histoplasmosis Blastomycosis Paracoccidioidomycosis
Male 126,218,201 473 (0.38) 267 (0.21) 56 (0.04) 110 (0.09) 40 (0.03)
Female 125,293,533 675 (0.54) 393 (0.31) 189 (0.15) 60 (0.05) 32 (0.03)
Total 251,511,734 1,148 660 245 171 72

Data are presented as n (%).

Prevalence rates of imported systemic mycoses by age.

Age (y) Population No. of patients (per 100,000)
Systemic mycoses Coccidioidomycosis Histoplasmosis Blastomycosis Paracoccidioidomycosis
0–9 24,121,916 172 (0.71) 114 (0.47) 38 (0.16) 13 (0.05) 7 (0.03)
10–19 33,591,851 63 (0.19) 39 (0.12) 11 (0.03) 6 (0.02) 7 (0.02)
20–29 34,475,220 102 (0.30) 62 (0.18) 28 (0.08) 8 (0.02) 4 (0.01)
30–39 41,636,105 159 (0.36) 103 (0.25) 35 (0.08) 8 (0.02) 13 (0.03)
40–49 43,928,536 206 (0.47) 118 (0.27) 44 (0.10) 28 (0.06) 16 (0.04)
50–59 35,035,189 179 (0.51) 101 (0.29) 38 (0.11) 26 (0.07) 14 (0.04)
60–69 20,749,025 133 (0.64) 63 (0.30) 26 (0.13) 40 (0.19) 4 (0.02)
70–79 13,170,523 97 (0.74) 48 (0.36) 15 (0.11) 29 (0.22) 5 (0.04)
80–89 4,227,934 34 (0.80) 10 (0.24) 9 (0.21) 13 (0.31) 2 (0.05)
90- 575,435 3 (0.52) 2 (0.35) 1 (0.17) 0 (0.00) 0 (0.00)
Total 251,511,734 1,148 660 245 171 72

Data are presented as n (%).

Prevalence rates of imported systemic mycoses by region.

Region Population No. of patients (per 100,000)
Systemic mycoses Coccidioidomycosis Histoplasmosis Blastomycosis Paracoccidioidomycosis
Gyeonggi 58,577,280 348 (0.59) 260 (0.44) 52 (0.09) 29 (0.05) 7 (0.01)
Seoul 51,173,741 219 (0.43) 101 (0.20) 69 (0.13) 38 (0.07) 11 (0.02)
Busan 17,772,034 59 (0.33) 27 (0.15) 17 (0.10) 9 (0.05) 6 (0.03)
Gyeongnam 16,401,116 92 (0.56) 38 (0.23) 14 (0.09) 9 (0.05) 31 (0.19)
Incheon 13,813,896 53 (0.38) 22 (0.16) 20 (0.14) 7 (0.05) 4 (0.03)
Gyeongbuk 13,438,345 35 (0.26) 17 (0.13) 7 (0.05) 8 (0.06) 3 (0.02)
Daegu 12,514,166 73 (0.58) 41 (0.33) 9 (0.07) 21 (0.17) 2 (0.02)
Chungnam 10,268,764 42 (0.41) 24 (0.23) 15 (0.15) 1 (0.01) 2 (0.02)
Jeonnam 9,581,516 56 (0.58) 40 (0.42) 11 (0.11) 4 (0.04) 1 (0.01)
Jeonbuk 9,333,685 35 (0.38) 17 (0.18) 6 (0.06) 10 (0.11) 2 (0.02)
Chungbuk 7,732,194 37 (0.48) 20 (0.26) 8 (0.10) 8 (0.10) 1 (0.01)
Gangwon 7,633,411 22 (0.29) 14 (0.18) 4 (0.05) 4 (0.05) 0 (0.00)
Daejeon 7,515,995 21 (0.28) 9 (0.12) 2 (0.03) 9 (0.12) 1 (0.01)
Gwangju 7,250,728 33 (0.46) 23 (0.32) 5 (0.07) 4 (0.06) 1 (0.01)
Ulsan 5,643,391 10 (0.18) 3 (0.05) 5 (0.09) 2 (0.04) 0 (0.00)
Jeju 2,861,472 13 (0.46) 4 (0.14) 1 (0.04) 8 (0.28) 0 (0.00)
Total 251,511,734 1,148 660 245 171 72

Data are presented as n (%).

Medical costs of imported systemic mycoses in Korea.

No. of patients Self-cost (Korean won) Insurance cost (Korean won) Total cost (Korean won)
Systemic mycosis Inpatient 38 61,757,950 210,985,310 272,743,260
Outpatient 1,110 31,680,200 80,102,530 111,782,730
Coccidioidomycosis Inpatient 19 56,691,790 190,083,600 246,775,390
Outpatient 641 22,511,660 61,636,340 84,148,000
Histoplasmosis Inpatient 10 1,767,940 8,922,980 10,690,920
Outpatient 235 4,782,740 7,085,050 11,867,790
Blastomycosis Inpatient 6 3,072,960 9,336,910 12,409,870
Outpatient 165 2,354,140 5,113,340 7,467,480
Paracoccidioidomycosis Inpatient 3 225,260 2,641,820 2,867,080
Outpatient 69 2,031,660 6,267,800 8,299,460
Table 1 Prevalence rates of imported systemic mycoses by year.

Data are presented as n (%).

Table 2 Prevalence rates of imported systemic mycoses by gender.

Data are presented as n (%).

Table 3 Prevalence rates of imported systemic mycoses by age.

Data are presented as n (%).

Table 4 Prevalence rates of imported systemic mycoses by region.

Data are presented as n (%).

Table 5 Medical costs of imported systemic mycoses in Korea.

Table 1

Table 2

Table 3

Table 4

Table 5

PHRP : Osong Public Health and Research Perspectives

About

Browse articles 

Editorial policies

For authors  

phrp 사이트 QRCODE
© Korea Disease Control and Prevention Agency.